2-methyl-D-ribose | 582310-87-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-D-ribose
• 英文别名: 2-c-Methylribose；(2R,3R,4R)-2,3,4,5-tetrahydroxy-2-methylpentanal
• CAS: 582310-87-0
• 化学式: C₆H₁₂O₅
• 分子量: 164.158
• InChiKey: OSBKZZCHLHZCDB-PBXRRBTRSA-N

物化性质

• 熔点：
  93-95 °C
• 沸点：
  399.1±35.0 °C(Predicted)
• 密度：
  1.418±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-C-甲基-D-核糖酸-1,4-内酯 生成 2-methyl-D-ribose
  参考文献：
  名称：

  Feast,A.A.J. et al., Acta Chemica Scandinavica (1947), 1965, vol. 19, p. 1127 - 1134

  摘要：

  DOI：

文献信息

• DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE
  申请人：Yamada Christina

  公开号：US20080085869A1

  公开（公告）日：2008-04-10

  Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.

  本文提供了一种双链寡核苷酸复合物，可以被输送到细胞、组织或生物体中，以沉默目标基因，而无需转染试剂的帮助。本公开的双链寡核苷酸复合物包括一个共轭基团，有助于将其输送到细胞、组织或生物体中。
• ANTIVIRAL THERAPEUTIC AGENTS
  申请人：Babu Yarlagadda S.

  公开号：US20090227524A1

  公开（公告）日：2009-09-10

  The invention provides compounds of Formula I: as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of Formula (I) are useful as anti-viral agents and/or as anti-cancer agents.

  该发明提供了如下的化合物I的公式，以及包含这些化合物的药物组合物，以及用于制备这些化合物的有用的合成方法和中间体。公式（I）的化合物可用作抗病毒剂和/或抗癌剂。
• FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE
  申请人：Vorobiev Alexei

  公开号：US20130261014A1

  公开（公告）日：2013-10-03

  3-alkynyl inosine analogs and their uses as universal bases are provided. The inosine analogues can be incorporated into nucleic acid primers and probes. They do not significantly destabilize nucleic acid duplexes. As a result, the novel nucleic acid primers and probes incorporating the inosine analogues can be used in a variety of methods. The analogs function unexpectedly well as universal bases. Not only do they stabilize duplexes substantially more than hypoxanthine opposite A, C, T, and G but they are also recognized in primers by polymerases, allowing efficient amplification.

  提供了3-炔基肌苷类似物及其作为通用碱基的用途。这些肌苷类似物可以被合并到核酸引物和探针中。它们不会显著破坏核酸双链。因此，包含这些肌苷类似物的新型核酸引物和探针可以用于各种方法。这些类似物意外地作为通用碱基发挥良好作用。它们不仅比嘌呤对A、C、T和G稳定双链更多，而且在引物中被聚合酶识别，从而实现高效扩增。
• HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS
  申请人：FRESENIUS KABI DEUTSCHLAND GMBH

  公开号：US20160311934A1

  公开（公告）日：2016-10-27

  The present invention relates to a hydroxyalkyl starch (HAS) derivative of formula (I) wherein F1 is a functional group comprising the group —NR′—, with R′ being H or alkyl; L is a spacer bridging F1 and S; wherein HAS′ is the remainder of the HAS molecule, R b and R c are —[(CR 1 R 2 ) m O] n —H and are the same or different from each other; R a is —[(CR 1 R 2 ) m O] n —H with HAS′ being the remainder of the hydroxyalkyl starch molecule, or R a is HAS″ with HAS′ and HAS″ together being the remainder of the hydroxyalkyl starch molecule; R 1 and R 2 are independently hydrogen or an alkyl group having from 1 to 4 carbon atoms, m is 2 to 4, wherein R 1 and R 2 are the same or different from each other in the m groups CR 1 R 2 ; n is from 0 to 6.

  本发明涉及一种羟基烷基淀粉（HAS）衍生物，其化学式为（I），其中F1是包含基团—NR′—的功能基团，其中R′为H或烷基；L是桥接F1和S的间隔物；其中HAS′是HAS分子的剩余部分，Rband Rcare —[(CR1R2)mO]n—H，且彼此相同或不同；Ra是—[(CR1R2)mO]n—H，其中HAS′是羟基烷基淀粉分子的剩余部分，或者Ra是HAS″，其中HAS′和HAS″一起是羟基烷基淀粉分子的剩余部分；R1和R2独立地是氢或具有1至4个碳原子的烷基基团，m为2至4，其中在m个CR1R2基团中，R1和R2彼此相同或不同；n为0至6。
• Novel 2'-C-methyl nucleoside derivatives
  申请人：Reddy Raja K.

  公开号：US20050182252A1

  公开（公告）日：2005-08-18

  Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:

  化合物I的配方、立体异构体以及其药用可接受的盐或前药，它们的制备以及它们用于治疗丙型肝炎病毒感染的用途被描述：